Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients

Transplantation

Volumn 63, Issue 11, 1997, Pages 1595-1601

  Falagas, Matthew E ^a   Arbo, Manuel ^a   Ruthazer, Robin ^a   Griffith, John L ^a   Werner, Barbara G ^b   Rohrer, Richard ^a   Freeman, Richard ^a   Lewis, W David ^c   Snydman, David R ^a,d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Massachusetts State Laboratory   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT SURVIVAL; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; LENGTH OF STAY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHILD; COSTS AND COST ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INFANT; LENGTH OF STAY; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS;

EID: 0030982213     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199706150-00010     Document Type: Article

References (35)

1. Wiesner RH, Marin E, Porayko MK, Steers JL, Krom RAF, Paya CV. Advances in liver transplantation. Gastroenterol Clin North Am 1993; 22(2): 351.
2. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg 1994; 220(3): 297.
3. Busuttil RW, Colonna JO, Hiatt JR, et al. The first 100 liver transplants at UCLA. Ann Surg 1987; 206(4): 387.
4. Evans RW, Manninen DL, Dong FB. An economic analysis of liver transplantation: costs, insurance coverage, and reimbursement. Gastroenterol Clin North Am 1993; 22: 451.
5. Muto P, Freeman RB, Haug CE, Lu A, Rohrer RJ. Liver transplant candidate stratification systems: implications for third-party payors and organ allocation. Transplantation 1994; 57: 306.
6. Menegaux F, Keefee EB, Baker E, et al. Comparison of transjugular and surgical portosystemic shunts on the outcome of liver transplantation. Arch Surg 1994; 129: 1018.
7. D'Alessandro AM, Ploeg RJ, Knechtle SJ, et al. Retransplantation of the liver: a seven-year experience. Transplantation 1993; 55: 1083.
8. Smith SD, Jackson RJ, Hannakan CJ, et al. Selective decontamination in pediatric liver transplants: a randomized prospective study. Transplantation 1993; 55: 1306.
9. Solomon H, Gonwa TA, Mor E, et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation 1993; 55: 87.
10. Lake JR, Gorman KJ, Esquivel CO, et al. The impact of immunosuppressive regimens on the cost of liver transplantation: results from the US FK506 multicenter trial. Transplantation 1995; 60: 1089.
11. Hemley KS, Lucey MR, Normolle DP, et al. A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology 1995; 21: 592.
12. Renald TH, Andrews WS, Schlatter MG, Conlin C. University of Wisconsin preservation solution compared with EuroCollins preservation solution in pediatric liver transplantation. J Pediatr Surg 1993; 28: 701.
13. Cofer JB, Klintmalm GB, Howard TK, et al. A comparison of UW with Eurocollins preservation solution in liver transplantation. Transplantation 1990; 49: 1088.
14. Spanier TB, Klein RD, Nasraway SA, et al. Multiple organ failure after liver transplantation. Crit Care Med 1995; 23: 466.
15. Brown RS, Lake JR, Ascher NL, Emond JC, Roberts JP. Determinants of the cost of liver transplantation [Abstract P-294]. Abstract book of the 15th annual meeting of the American Society of Transplant Physicians, Dallas, TX, May 1996: 246.
16. McCarthy JM, Karim MA, Krueger H, Keown PA. The cost impact of cytomegalovirus in renal transplant recipients. Transplantation 1993; 55: 1277.
17. Snydman DR, Werner BG, Dougherty NN, and the Boston Center for Liver Transplantation CMVIG Study Group. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo- controlled trial. Ann Intern Med 1993; 119: 984.
18. Falagas ME, Snydman DR, Ruthazer R, and the Boston Center for Liver Transplantation CMVIG Study Group. The incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Transplantation 1996; 61: 1716.
19. Falagas ME, Snydman DR, Griffith J, and the Boston Center for Liver Transplantation CMVIG Study Group. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 1996; 23: 468.
20. SAS Institute Inc. SAS/STAT user's guide, version 6, 4th ed. Cary, NC: SAS Institute Inc., 1989.
21. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical approach to infection in the immunocompromised host, 3rd ed. New York: Plenum Medical Book, 1994: 647.
22. Stratta RJ, Shaefer MS, Markin RS, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989; 124: 1443.
23. Ho M. Cytomegalovirus biology and infection, 2nd ed. New York: Plenum, 1991: 252.
24. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344: 1737.
25. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
26. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644.
27. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185.
28. Rand KH, Pollard RB, Merigan TC. Increased pulmonary super-infections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 1978; 298(17): 951.
29. Falagas ME, Snydman DR, Ruthazer R, et al. Primary cytomegalovirus infection in liver transplantation: comparison of infections transmitted via donor organs and via transfusions. Clin Infect Dis 1996; 23: 292.
30. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59(3): 361.
31. Motschman TL, Taswell HF, Brecher ME, et al. Intraoperative blood loss and patient and graft survival in orthotopic liver transplantation: their relationship to clinical and laboratory data. Mayo Clin Proc 1989; 64: 346.
32. Cuervas-Mons V, Millan I, Gavaler JS, Starzl TE, Van Thiel DH. Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. Hepatology 1986; 6(5): 922.
33. Rimola A, Gavaler JS, Schade RR, El-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93: 148.
34. Busuttil RW, Colonna JO, Hiatt JR, et al. The first 100 liver transplants at UCLA. Ann Surg 1987; 206(4): 387.
35. Paya CV, Hermans PE, Smith TF, et al. Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection. Transplantation 1988; 46: 229.